China CAS:187164-19-8 Manufacturer

We believe that prolonged time period partnership is really a result of top of the range, benefit added provider, prosperous knowledge and personal contact for CAS:187164-19-8, we could solve our customer problems asap and do the profit for our customer. For those who need superior provider and excellent , pls choose us , thanks !
CAS:187164-19-8, We have constructed strong and long co-operation relationship with an enormous quantity of companies within this business overseas. Immediate and specialist after-sale service supplied by our consultant group has happy our buyers. Detailed Info and parameters from the merchandise will probably be sent to you for any thorough acknowledge. Free samples may be delivered and company check out to our corporation. n Portugal for negotiation is constantly welcome. Hope to get inquiries type you and construct a long-term co-operation partnership.

Hot Products

  • Dutasteride

    Dutasteride

    Dutasteride has EP, USP, CP, IP, JP specification. CEP and FDA available.

    CAS:164656-23-9

  • Eplerenone

    Eplerenone

    Eplerenone has EP specifications. CEP available and FDA approved.

    CAS:107724-20-9

  • 16-Dehydropregnenolone Acetate (16-DPA)

    16-Dehydropregnenolone Acetate (16-DPA)

    16-Dehydropregnenolone Acetate (16-DPA) is the dehydration product of Pregnenolone Acetate..

    CAS:979-02-2

  • Oxcarbazepine

    Oxcarbazepine

    Oxcarbazepine has CP, EP and USP specifications. CEP and DMF available, GMP approved.

    CAS:28721-07-5

  • Cyproterone Acetate Tablets

    Cyproterone Acetate Tablets

    Cyproterone Acetate Tablets Specifications:50mg*24
    Indications:Anti-androgen
  • Epiandrosterone

    Epiandrosterone

    Epiandrosterone is a steroid hormone with weak androgenic activity. It is a metabolite of testosterone and dihydrotestosterone (DHT).

    CAS:481-29-8

Send Inquiry

X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept